Preventing CVD in Type 2 Diabetes Patients
Type 2 diabetes is associated with a substantially increased risk of events such as heart attack and stroke. BP levels are on average higher among individuals with diabetes and increased BP is a well-established risk factor for people with diabetes.
The researchers, led by Kazem Rahimi, DM, MSc, of the George Institute for Global Health, University of Oxford (UK), conducted a review and meta-analysis of large-scale randomised controlled trials of BP-lowering treatment including patients with diabetes, published between January 1966 and October 2014. Their review of relevant literature found 40 trials to be of low risk of bias (100,354 participants), which were included in the analysis to assess the connection between BP-lowering treatment and vascular disease in type 2 diabetes.
The research team also observed that the associations between BP-lowering treatments and outcomes were not significantly different, irrespective of drug class, except for stroke and heart failure.
While proportional associations of BPlowering treatment for most outcomes studied were diminished below a systolic BP level of 140 mm Hg, data indicated that further reduction below 130 mm Hg is associated with a lower risk of stroke, albuminuria, and retinopathy, potentially leading to net benefits for many individuals at high risk for those outcomes.
“Among patients with type 2 diabetes, BP lowering was associated with improved mortality and other clinical outcomes. These findings support the use of medications for BP lowering in these patients,” the research team pointed out.
Lowering BP in individuals with diabetes is an area of current controversy, with particular debate surrounding who should be offered therapy and the BP targets to be achieved.
In an accompanying editorial, Bryan Williams, MD, of University College London, writes: “These findings are timely, clear, and important and lend support to current guideline recommendations to consider offering patients with type 2 diabetes antihypertensive therapy when their systolic BP is 140 mm Hg or greater, aiming for a target systolic BP toward 130 mm Hg but not usually lower than this.
However, Emdin et al.'s study suggests that for some patients, these treatment thresholds and targets might be "too conservative", especially for optimally reducing the risk of stroke and the development or progression of albuminuria, Dr. Williams notes. "This conundrum highlights the problems with clinician overreliance on guidelines and guideline overdependence on an often, uncritical adoption of evidence, despite the limitations of the clinical trials. Guidelines are just that, and are necessarily conservative in providing population-based recommendations that physicians must interpret in the context of the individual patient being treated.”
By 2030, it is estimated that there will be at least 400 million individuals with type 2 diabetes worldwide.
Image Credit: Google Images
Published on : Tue, 10 Feb 2015
The CNAP® Monitor represents the next generation of noninvasive patient monitoring by merging the advantages of noninvasive, risk‐free methods with the benefits of continuity in the same accuracy as invasive standards. The advanced parameter set enables...
The Task Force® Monitor is the all‐in‐one workstation for continuous noninvasive hemodynamic and autonomic assessment. It is the state‐of‐the‐art diagnostic tool to study syncope and autoregulation of blood pressure and has further established as an...